All Stories

  1. Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update

    Article • Liver Cancer, March 2023, Karger Publishers

    Masatoshi Kudo

  2. Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

    Article • Liver Cancer, March 2023, Karger Publishers

    Masatoshi Kudo

  3. Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity

    Article • Liver Cancer, January 2023, Karger Publishers

    Masatoshi Kudo

  4. Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma

    Article • Liver Cancer, January 2023, Karger Publishers

    Masatoshi Kudo

  5. IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study

    Article • Liver Cancer, November 2022, Karger Publishers

    Masatoshi Kudo

  6. Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and TACE to Achieve Synergistic Effects

    Article • Liver Cancer, October 2022, Karger Publishers

    Masatoshi Kudo

  7. Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-unsuitable Intermediate-stage Hepatocellular Carcinoma

    Article • Liver Cancer, July 2022, Karger Publishers

    Masatoshi Kudo

  8. Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

    Article • Liver Cancer, January 2022, Karger Publishers

    Masatoshi Kudo

  9. Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass

    Article • Liver Cancer, January 2022, Karger Publishers

    Masatoshi Kudo

  10. Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?

    Article • Liver Cancer, January 2022, Karger Publishers

    Masatoshi Kudo

  11. Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma

    Article • Liver Cancer, December 2021, Karger Publishers

    Masatoshi Kudo

  12. Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy

    Article • Liver Cancer, February 2021, Karger Publishers

    Masatoshi Kudo

  13. Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma

    Article • Liver Cancer, January 2021, Karger Publishers

    Masatoshi Kudo

  14. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update

    Article • Liver Cancer, January 2021, Karger Publishers

    Masatoshi Kudo

  15. Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma

    Article • Liver Cancer, January 2021, Karger Publishers

    Masatoshi Kudo

  16. Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?

    Article • Liver Cancer, January 2021, Karger Publishers

    Masatoshi Kudo

  17. Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma

    Article • Liver Cancer, January 2021, Karger Publishers

    Masatoshi Kudo

  18. A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion

    Article • Liver Cancer, January 2021, Karger Publishers

    Masatoshi Kudo

  19. Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

    Article • Liver Cancer, October 2020, Karger Publishers

    Masatoshi Kudo

  20. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma

    Article • Liver Cancer, August 2020, Karger Publishers

    Masatoshi Kudo

  21. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma

    Article • Liver Cancer, June 2020, Karger Publishers

    Masatoshi Kudo

  22. A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy

    Article • Liver Cancer, January 2020, Karger Publishers

    Masatoshi Kudo

  23. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

    Article • Liver Cancer, January 2020, Karger Publishers

    Masatoshi Kudo

  24. Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma

    Article • Liver Cancer, January 2020, Karger Publishers

    Masatoshi Kudo

  25. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update

    Article • Liver Cancer, January 2020, Karger Publishers

    Masatoshi Kudo

  26. Management of Hepatocellular Carcinoma in Japan: Current Trends

    Article • Liver Cancer, December 2019, Karger Publishers

    Masatoshi Kudo

  27. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

    Article • Gut, December 2019, BMJ

    Masatoshi Kudo

  28. Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials

    Article • Liver Cancer, January 2019, Karger Publishers

    Masatoshi Kudo

  29. Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

    Article • Liver Cancer, January 2019, Karger Publishers

    Masatoshi Kudo

  30. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE

    Article • Liver Cancer, January 2019, Karger Publishers

    Masatoshi Kudo

  31. Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies

    Article • Liver Cancer, January 2019, Karger Publishers

    Masatoshi Kudo

  32. Sorafenib: key lessons from over 10 years of experience

    Article • Expert Review of Anticancer Therapy, December 2018, Taylor & Francis

    Masatoshi Kudo

  33. Novel method of biliary cannulation for patients with Roux-en-Y anastomosis using a unique, uneven, double-lumen cannula (Uneven method)

    Article • Digestive Endoscopy, October 2018, Wiley

    Masatoshi Kudo

  34. Endoscopic nasobiliary drainage tube-guided scope insertion technique for internal drainage in a case of difficult selective biliary duct guiding

    Article • Digestive Endoscopy, September 2018, Wiley

    Masatoshi Kudo

  35. Clinical efficacy and safety of endoscopic ultrasound-guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study

    Article • Digestive Endoscopy, August 2018, Wiley

    Masatoshi Kudo

  36. Dual-energy computed tomography for non-invasive staging of liver fibrosis: Accuracy of iodine density measurements from contrast-enhanced data

    Article • Hepatology Research, July 2018, Wiley

    Masatoshi Kudo

  37. Cannulation method for intradiverticular papilla with long oral protrusion using biopsy forceps for axis alignment

    Article • Digestive Endoscopy, July 2018, Wiley

    Masatoshi Kudo

  38. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma

    Article • Hepatology Research, June 2018, Wiley

    Masatoshi Kudo

  39. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method

    Article • Hepatology Research, May 2018, Wiley

    Masatoshi Kudo

  40. Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms

    Article • Digestive Endoscopy, May 2018, Wiley

    Masatoshi Kudo

  41. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting

    Article • Liver International, January 2018, Wiley

    Masatoshi Kudo

  42. A case of small invasive gastric cancer arising from Helicobacter pylori- negative gastric mucosa: Fundic gland-type adenocarcinoma

    Article • JGH Open, October 2017, Wiley

    Masatoshi Kudo, Yoriaki Komeda

  43. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tract

    Article • Journal of Gastroenterology and Hepatology, September 2017, Wiley

    Masatoshi Kudo

  44. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma

    Article • Cancer Science, September 2017, Wiley

    Masatoshi Kudo

  45. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesions

    Article • Digestive Endoscopy, July 2017, Wiley

    Masatoshi Kudo

  46. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey

    Article • Hepatology, June 2017, Wiley

    Masatoshi Kudo

  47. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease

    Article • Journal of Gastroenterology and Hepatology, September 2016, Wiley

    Masatoshi Kudo

  48. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study

    Article • Liver International, April 2016, Wiley

    Masatoshi Kudo

  49. Report of the 19th follow-up survey of primary liver cancer in Japan

    Article • Hepatology Research, April 2016, Wiley

    Masatoshi Kudo

  50. Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)

    Article • Hepatology Research, August 2015, Wiley

    Masatoshi Kudo

  51. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

    Article • Hepatology, November 2014, Wolters Kluwer Health

    Masatoshi Kudo

  52. Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma

    Article • Hepatology, April 2014, Wiley

    Masatoshi Kudo